Clinical Trial

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Name: Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) — clinical trial record (NCT05005975)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

To evaluate the long-term safety and tolerability of oral dersimelagon.

Protocol Amendment History 1 change

notable Trial sites reduced: 51 -> 45 locations 2026-08-12

Trial Details

NCT Number	NCT05005975
Lead Sponsor	Tanabe Pharma America, Inc.
Conditions	EPP, XLP
Enrollment	301 participants
Start Date	2021-08-10
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-11